Add to ORKGPrediction of the responses to neoadjuvant chemotherapy (NACT) can improve the treatment of patients with ad-vanced breast cancer. Genes and proteins predictive of chemoresistance have been extensively studied in breast cancer tissues. However, noninvasive serum biomarkers capable of such prediction have been rarely exploited. Here, we performed profiling of N-glycosylated proteins in serum from fifteen advanced breast cancer patients (ten patients sensitive to and five patients resistant to NACT) to discover serum biomarkers of chemoresistance using a label-free liquid chromatography-tandem MS method. By performing a series of statistical analyses of the pro-teomic data, we selected thirteen biomarker candidates and tested their differenti...
Background:Neoadjuvant chemotherapy is a standard treatment for locally advanced breast cancer howev...
Background Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and usu...
Breast cancer is a clinically heterogeneous disease, which necessitates a variety of treatments and ...
Despite the increasing use of neoadjuvant chemotherapy (NAC) in HER2-positive breast cancer (BC) pat...
Background:Chemotherapy resistance is a major obstacle in effective neoadjuvant treatment for locall...
Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging...
Although doxorubicin (Doxo) and docetaxel (Docet) in combination are widely used in treatment regime...
Introduction: Chemotherapy resistance is a major obstacle in effective neoadjuvant treatment for est...
Breast cancer is one of the three most common cancers along with lung and colon cancer. It is a lead...
Neoadjuvant chemotherapy (NACT) outcomes vary according to breast cancer (BC) subtype. Since patholo...
This review describes and discusses the advantages and limitations of proteomic approaches in the id...
Background:Neoadjuvant chemotherapy is a standard treatment for locally advanced breast cancer howev...
Background Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and usu...
Breast cancer is a clinically heterogeneous disease, which necessitates a variety of treatments and ...
Despite the increasing use of neoadjuvant chemotherapy (NAC) in HER2-positive breast cancer (BC) pat...
Background:Chemotherapy resistance is a major obstacle in effective neoadjuvant treatment for locall...
Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging...
Although doxorubicin (Doxo) and docetaxel (Docet) in combination are widely used in treatment regime...
Introduction: Chemotherapy resistance is a major obstacle in effective neoadjuvant treatment for est...
Breast cancer is one of the three most common cancers along with lung and colon cancer. It is a lead...
Neoadjuvant chemotherapy (NACT) outcomes vary according to breast cancer (BC) subtype. Since patholo...
This review describes and discusses the advantages and limitations of proteomic approaches in the id...
Background:Neoadjuvant chemotherapy is a standard treatment for locally advanced breast cancer howev...
Background Triple-negative breast cancer (TNBC) accounts for 15–20% of all breast cancers and usu...
Breast cancer is a clinically heterogeneous disease, which necessitates a variety of treatments and ...